Biomarin Pharmaceutical Inc. (BMRN)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin: Amicus Buyout Sparks My Enthusiasm
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript
BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2025 Earnings Call October 27, 2025 4:30 PM EDT Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Julian Pino Christopher Raymond - Raymond James & Associates, Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Presentation Operator Hello, and welcome to the BioMarin Pharmaceutical Third Quarter 2025 Conference Call. [Operator Instructions].
Biomarin Up After Q3 Earnings: Here's Everything You Need to Know
BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading.
